目的: 探究Her2阴性晚期胃癌患者采用阿帕替尼进行治疗的疗效及毒副作用。方法: 按照不同治疗方法将本院就诊的Her2阴性晚期胃癌患者分为阿帕替尼组(AP组)和替吉奥组(TI组),各46例,分析比较两组患者的临床疗效、生活质量、毒副作用及远期疗效。结果: 治疗后,AP组11例、TI组6例患者出现部分缓解,AP组患者RR、DCR数值明显比TI组高(P＜0.05);AP组患者生活质量明显优于TI组 (P＜0.05)。AP组和TI组患者均出现血小板减少、蛋白尿、肝功能异常等不良反应,但未出现Ⅳ级毒副作用,其中AP组患者高血压、血小板减少的发病率分别为63.52 %、76.73 %,TI组患者发病率分别为62.45 %、78.11 %, AP组出现毒副作用的患者人数与TI组比较无明显差异(P＞0.05)。随访3年结果显示,AP组患者3年生存率为10.86 %,TI组患者为0,AP组患者总生存率明显高于TI组(P＜0.05)。结论: 阿帕替尼对Her2阴性晚期胃癌患者的临床疗效及远期治疗效果较佳,虽然治疗后也会出现一定的毒副作用,但与替吉奥治疗后出现的毒副作用相近,且患者身体承受程度较佳。阿帕替尼可以用于临床治疗晚期胃癌。
Objective: To explore the efficacy and toxic side effects of apatinib in patients with ADVANCED gastric cancer with Her2 negative. Methods: Patients with Her2 negative advanced gastric cancer in our hospital were divided into apatinib group (AP group) and Tigio group (TI group) according to different treatment methods, with 46 patients in each group. The clinical efficacy, quality of life, toxic side effects and long-term efficacy of AP group and TI group were observed and compared. Results: After treatment, partial remission occurred in 11 patients in the AP group and 6 patients in the TI group. RR and DCR values in the AP group were significantly higher than those in the TI group (P＜0.05). Compared with TI group, the quality of life in AP group was significantly better than TI group (P＜0.05). The AP group and TI group showed thrombocytopenia, proteinuria, abnormal liver function and other toxic and side effects, but there was no class ⅳ toxic and side effects. The incidence rates of hypertension and thrombocytopenia were 63.52 % and 76.73 % in the AP group, and 62.45 % and 78.11 % in the TI group, respectively. There was no significant difference in the number of patients with adverse effects between the AP group and the TI group (P＞0.05). The 3-year follow-up results showed that the 3-year survival rate of AP group was 10.86 %, and the 3-year survival rate of TI group was 0 %. The overall survival rate of AP group was significantly higher than that of TI group (P＜0.05). Conclusion: Apatinib has good clinical efficacy and long-term treatment effect in patients with ADVANCED GASTRIC cancer with Her2 negative. Although there are certain toxic and side effects after treatment, they are similar to those after treatment with gio, and patients' body tolerance is better. Apatinib can be used to treat advanced gastric cancer.
[1] 耿芳, 尹航, 李哲,等. 胃癌靶向治疗的临床进展[J].临床药物治疗杂志, 2017, 15(2):1-6.
[2] 盛剑秋, 金鹏. 早期胃癌内镜诊断进展[J].中华消化杂志, 2018, 38(3):149-151.
[3] 余佩武, 江志伟, 郝迎学, 等. 胃癌胃切除手术加速康复外科专家共识(2016版)[J].中华消化外科杂志, 2017, 16(1):14-18.
[4] 黄光钺, 陈华敏, 吴煌福,等. 腹腔镜辅助远端胃癌D2根治术的疗效及安全性探讨[J].疑难病杂志, 2017,16(12):1252-1256.
[5] Areia M, Spaander MC, Kuipers EJ, et al. Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk[J].United European Gastroenterol J, 2018, 6(2):205-219.
[6] 刘晓, 窦利州, 薛丽燕,等. 早期胃癌内镜黏膜下剥离术与外科手术临床效果及生存质量的回顾性对比研究[J].中华消化内镜杂志, 2017, 34(8):543-548.
[7] Carneiro F. Hereditary gastric cancer[J].European J Cancer, 2018, 92(2):231-234.
[8] 李琪, 史晓宇, 赵丽霞,等. 阿帕替尼联合化疗用于二线治疗失败晚期卵巢癌的临床观察[J].河北医科大学学报, 2017, 38(12):1384-1387.
[9] 韩璐璐. 阿帕替尼联合伊立替康治疗晚期胃癌患者的疗效和安全性分析[D].沈阳:中国医科大学,2020.
[10] 侯艳林. 艾迪注射液联合CAFI化疗方案对原发性肝癌患者KPS评分及肿瘤疾病控制率的影响[J].北方药学, 2018, 15(7):56-57.
[11] Gu L, Lu LS, Zhou DL, et al. UCA1 promotes cell proliferation and invasion of gastric cancer by targeting CREB1 sponging to miR-590-3p[J].Cancer Med, 2018, 7(4):1253-1263.
[12] 韩婷婷, 石明伟, 王凡,等. 阿帕替尼治疗晚期胃癌的临床疗效观察[J].现代肿瘤医学, 2018,26(4):557-559.
[13] 张惠博. 阿帕替尼治疗晚期胃癌的研究进展[J].肿瘤学杂志, 2019, 25(6):573-576.
[14] Li J , Qin S , Xu J , et al. Randomized, double-blind, placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J].J Clin Oncol, 2016,34(13):1448-1454.
[15] 倪田田, 李平. 益气养阴通络方联合阿帕替尼和替加氟治疗晚期胃癌临床观察[J].辽宁中医药大学学报, 2019,78(4):120-123.
[16] 陈新义,肖正红. 阿帕替尼联合替吉奥在晚期食管癌二线治疗中的临床效果及药物不良反应[J].临床医学研究与实践,2022,7(5):31-33.
[17] 吴天峰,林春丽,崔杰. 替吉奥+奥沙利铂+阿帕替尼方案对Ⅳ期胃癌患者的转化治疗效果[J].癌症进展,2021,19(23):2428-2431.
[18] 黄志平,俞慧群,赵昕,等. 替吉奥治疗胃癌的循证评价[J].中国现代应用药学,2020,37(21):2644-2648.
[19] 李元元, 刘珏, 周庆,等. 阿帕替尼致2例严重不良反应分析[J].中国药师, 2017, 20(11):2037-2038.
[20] 沈雪敬, 张伟杰, 马志俊,等. 阿帕替尼治疗晚期乳腺癌疗效与安全性分析[J].中华肿瘤防治杂志, 2019,26(8):549-553.
